Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: Amgenís R&D Chief Expresses Great Optimism About Omecamtiv Mecarbil for Treating Congestive Heart Failure (CYTK, Buy, $6.53)

Purpose of This Report

I have written frequently about omecamtiv mecarbil, Cytokineticsí extremely promising new drug for congestive heart failure…
Read more…

Cytokinetics: Extremely Encouraging News from Amgen on Omecamtiv (CYTK, Buy, $6.54)

Introduction

The Cowen conference in Boston is going on this week. I consider Cowen to have the best and broadest coverage…
Read more…